Compounds > ticlopidine
Page last updated: 2024-11-05

ticlopidine and Adverse Drug Event

ticlopidine has been researched along with Adverse Drug Event in 36 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
" This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery."7.78Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012)
"Clinicians will be able to understand the safety profile of using different doses of clopidogrel and the incidence of bleeding when used alone or in combination with other antiplatelet agents."4.87The safety of clopidogrel. ( Kleiman, NS; Mangalpally, KK, 2011)
"Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period."3.83Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016)
"This ecological comparison of bleeding reports and dispensed prescriptions showed a signal towards a higher prevalence of bleeding reports in women on clopidogrel treatment while the opposite was found for low-dose aspirin."3.80Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. ( Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B, 2014)
" This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery."3.78Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012)
" Bleeding caused by some combination of nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase-2-selective NSAIDS, aspirin, and clopidogrel was the most common reason for ADR-related MICU admissions."3.74Admissions to a medical intensive care unit related to adverse drug reactions. ( Rivkin, A, 2007)
" Secondly, the efficacy and safety disparity of clopidogrel, statins and irinotecan each among races and genetic variants are discussed to illustrate that pharmacogenetic knowledge is important for the interpretation and prediction of drug interaction-induced adverse events, whereas drug interaction -induced adverse events are equally informative for identifying genes-based mechanisms involved."2.46Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. ( Bai, JP, 2010)
"Patients in nursing homes are often treated with many drugs concurrently (polypharmacy), which increases the risk of drug-drug interactions."1.40[Drug-drug interactions in nursing home patients]. ( Slørdal, L; Spigset, O; Staurset, HB; Søraas, IA, 2014)
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."1.37FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)
"Bupropion is an atypical antidepressant that is biotransformed in humans to its major active metabolite hydroxybupropion by cytochrome P450 2B6 (CYP2B6)."1.37Drug interaction study between bupropion and ticlopidine in male CF-1 mice. ( Hassan, HE; Moeller, BM; Molnari, JC; Myers, AL, 2011)
"We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)."1.36Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010)
" It is concluded that MEGX test widens opportunities for personalization and safe pharmacotherapy."1.36[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity]. ( Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS, 2010)
"Ticlopidine has a relative high rate of side-effects."1.34Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. ( Fukushima, K; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T; Okuno, T; Sakakibara, M; Shimizu, Y, 2007)
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."1.32Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (19.44)29.6817
2010's28 (77.78)24.3611
2020's1 (2.78)2.80

Authors

AuthorsStudies
Matthews, EJ1
Kruhlak, NL1
Weaver, JL1
Benz, RD1
Contrera, JF1
Chen, M1
Vijay, V1
Shi, Q2
Liu, Z2
Fang, H2
Tong, W2
Dawson, S1
Stahl, S1
Paul, N1
Barber, J1
Kenna, JG1
Ding, D1
Kelly, R1
Sakatis, MZ1
Reese, MJ1
Harrell, AW1
Taylor, MA4
Baines, IA1
Chen, L1
Bloomer, JC1
Yang, EY1
Ellens, HM1
Ambroso, JL1
Lovatt, CA1
Ayrton, AD1
Clarke, SE1
Godwin, AC3
Hoque, S3
Bennett, CL3
Parker, WA1
Bhatt, DL1
Prats, J1
Day, JRS1
Steg, PG1
Stone, GW1
Hamm, CW1
Mahaffey, KW1
Price, MJ1
Gibson, CM1
White, HD1
Storey, RF1
Martin, AC1
Houssany-Pissot, S1
Zlotnik, D1
Taylor, G1
Godier, A1
Tan, SSN1
Fong, AYY1
Mejin, M1
Gerunsin, J1
Kong, KL1
Chin, FYY1
Tiong, LL1
Lim, MSH1
Asri, S1
Khiew, NZ1
Voon, CY1
Mohd Amin, NH1
Cham, YL1
Koh, KT1
Oon, YY1
Ong, TK1
Kim, SG1
Shim, KS1
Lee, DW1
Kim, EJ1
Lee, SG1
Lee, JH1
An, JH1
Blais, DM1
Zukkoor, SM1
Hayes, C1
Pickworth, KK1
Porter, K1
Firstenberg, MS1
Rydberg, DM1
Holm, L1
Mejyr, S1
Loikas, D1
Schenck-Gustafsson, K1
von Euler, M1
Wettermark, B1
Malmström, RE1
Søraas, IA1
Staurset, HB1
Slørdal, L1
Spigset, O1
Tong, V1
Raynor, DK1
Blalock, SJ1
Aslani, P1
Koziolova, NA1
Nishimura, AA1
Shirts, BH1
Salama, J1
Smith, JW1
Devine, B1
Tarczy-Hornoch, P1
Noh, Y1
Lee, J1
Shin, S1
Lim, HS1
Bae, SK1
Oh, E1
Kim, GJ1
Kim, JH1
Lee, S1
Payne, CD1
Li, YG1
Brandt, JT1
Jakubowski, JA1
Small, DS1
Farid, NA1
Salazar, DE1
Winters, KJ1
Heer, T1
Juenger, C1
Gitt, AK1
Bauer, T1
Towae, F1
Zahn, R1
Senges, J1
Zeymer, U1
Mirabella, F1
Francaviglia, B1
Capodanno, D1
Di Salvo, ME1
Galassi, AR1
Ussia, GP1
Capranzano, P1
Tamburino, C1
Diedler, J1
Ahmed, N1
Sykora, M1
Uyttenboogaart, M1
Overgaard, K1
Luijckx, GJ1
Soinne, L1
Ford, GA1
Lees, KR1
Wahlgren, N1
Ringleb, P1
Kramer, E1
Hadad, E1
Westreich, M1
Shalom, A1
Bai, JP1
Hassan, AE1
Zacharatos, H1
Vazquez, G1
Rodriguez, GJ1
Suri, MF1
Tummala, RP1
Taylor, RA1
Qureshi, AI1
Donohue, MM1
Tirschwell, DL1
Mangalpally, KK1
Kleiman, NS1
Sivkov, AS1
Paukov, SV1
Ruvinov, IuV1
Kukes, IV1
Machado-Alba, JE1
Giraldo-Giraldo, C1
Moncada-Escobar, JC1
Molnari, JC1
Hassan, HE1
Moeller, BM1
Myers, AL1
Messinger-Rapport, BJ1
Morley, JE1
Thomas, DR1
Gammack, JK1
Dolgin, E1
Miyaji, Y1
Makino, C1
Kurihara, A1
Suzuki, W1
Okazaki, O1
Boulé, S1
Marquié, C1
Vanesson-Bricout, C1
Kouakam, C1
Brigadeau, F1
Guédon-Moreau, L1
Acheré, C1
Goéminne-Boulé, C1
Lacroix, D1
Klug, D1
Kacet, S1
Fukushima, K1
Kobayashi, Y1
Okuno, T1
Nakamura, Y1
Sakakibara, M1
Nakayama, T1
Kuroda, N1
Miyazaki, A1
Shimizu, Y1
Komuro, I1
Rivkin, A1
Gallagher, P1
Ryan, C1
Byrne, S1
Kennedy, J1
O'Mahony, D1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162]Phase 38,882 participants (Actual)Interventional2006-04-30Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00385138]Phase 35,364 participants (Actual)Interventional2006-09-30Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843]1,000 participants (Anticipated)Interventional2010-04-30Recruiting
Pharmacist-led Intervention to Reduce Potentially Inappropriate Prescription in Elderly and Polypharmacy Patients at Primary Care Setting (PHARM-PC) Cluster Randomized Trial[NCT02224833]549 participants (Actual)Interventional2015-01-31Completed
Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Using STOPP/START Criteria[NCT01467050]Phase 4732 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI

(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI

Interventionparticipants (Number)
Cangrelor Arm127
Clopidogrel Arm141

Incidence of ACUITY Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm151
Clopidogrel Arm120

Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)

excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm78
Clopidogrel Arm65

Incidence of All Cause Mortality

(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization

Interventionparticipants (Number)
Cangrelor Arm116
Clopidogrel Arm120

Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm34
Clopidogrel Arm29

Incidence of All-cause Mortality and MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm285
Clopidogrel Arm261

Incidence of All-cause Mortality or MI

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm321
Clopidogrel Arm298

Incidence of All-cause Mortality, MI or IDR

(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm343
Clopidogrel Arm327

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm290
Clopidogrel Arm276

Incidence of GUSTO Severe / Life-threatening Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm10
Clopidogrel Arm11

Incidence of IDR

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm44
Clopidogrel Arm52

Incidence of MI

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm297
Clopidogrel Arm276

Incidence of Stroke

(NCT00305162)
Timeframe: randomization through 30 days after randomization

Interventionparticipants (Number)
Cangrelor Arm5
Clopidogrel Arm7

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm19
Clopidogrel Arm14

Individual Incidence of All-cause Mortality

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm8
Clopidogrel Arm5

Individual Incidence of IDR

(NCT00305162)
Timeframe: randomization through 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Arm13
Clopidogrel Arm23

Incidence of Stroke

"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization

,
Interventionparticipants (Number)
primary hemorrhagicinfarction with hemorrhagic conversioncerebral infarctionuncertain type
Cangrelor Arm1050
Clopidogrel Arm0070

Incidence of ACUITY Major Bleeding

Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor145
Clopidogrel91

Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm

Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm. (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor43
Clopidogrel29

Incidence of All-cause Mortality

mITT population (NCT00385138)
Timeframe: randomization through 1 year post randomization

Interventionparticipants (Number)
Cangrelor94
Clopidogrel113

Incidence of All-cause Mortality

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor35
Clopidogrel45

Incidence of All-cause Mortality

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor6
Clopidogrel18

Incidence of All-cause Mortality or MI

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor213
Clopidogrel233

Incidence of All-cause Mortality or MI

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor180
Clopidogrel204

Incidence of All-cause Mortality, MI, or IDR

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor227
Clopidogrel249

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

mITT population; (composite incidence) (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor185
Clopidogrel210

Incidence of GUSTO Severe / Life-threatening

Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor9
Clopidogrel6

Incidence of IDR

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor37
Clopidogrel46

Incidence of IDR

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor19
Clopidogrel24

Incidence of MI

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor189
Clopidogrel201

Incidence of MI

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor177
Clopidogrel191

Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]

mITT population A patient could have multiple procedural events. (NCT00385138)
Timeframe: During index PCI

Interventionparticipants (Number)
Cangrelor122
Clopidogrel142

Incidence of Stent Thrombosis

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor15
Clopidogrel28

Incidence of Stent Thrombosis

mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor5
Clopidogrel16

Incidence of Stroke

mITT (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor7
Clopidogrel5

Incidence of Stroke

mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization

Interventionparticipants (Number)
Cangrelor6
Clopidogrel5

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major

Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization

Interventionparticipants (Number)
Cangrelor4
Clopidogrel9

Reviews

5 reviews available for ticlopidine and Adverse Drug Event

ArticleYear
[Management of the bleeding risk associated with antiplatelet agents].
    La Revue de medecine interne, 2017, Volume: 38, Issue:7

    Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans

2017
[Antiplatelet therapy in atherosclerosis of various localizations: acute and stable States].
    Kardiologiia, 2014, Volume: 54, Issue:4

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Drug Therapy, Combination; Drug-Related Side Effe

2014
Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.
    Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:1

    Topics: Administration, Oral; Camptothecin; Clopidogrel; Drug Evaluation; Drug Interactions; Drug-Related Si

2010
Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.
    Current neurology and neuroscience reports, 2011, Volume: 11, Issue:1

    Topics: Anticoagulants; Clopidogrel; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse R

2011
The safety of clopidogrel.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:1

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; H

2011

Trials

2 trials available for ticlopidine and Adverse Drug Event

ArticleYear
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si

2017
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Platelets, 2008, Volume: 19, Issue:4

    Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions;

2008

Other Studies

29 other studies available for ticlopidine and Adverse Drug Event

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru

2004
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des

2011
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters

2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
    PLoS computational biology, 2011, Volume: 7, Issue:12

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme

2012
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions.
    Cancer treatment and research, 2022, Volume: 184

    Topics: Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Thalidomide; Ti

2022
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions.
    Cancer treatment and research, 2022, Volume: 184

    Topics: Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Thalidomide; Ti

2022
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions.
    Cancer treatment and research, 2022, Volume: 184

    Topics: Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Thalidomide; Ti

2022
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions.
    Cancer treatment and research, 2022, Volume: 184

    Topics: Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Thalidomide; Ti

2022
Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents.
    Pharmacogenomics, 2017, Volume: 18, Issue:13

    Topics: Alleles; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Drug-Elutin

2017
Intramuscular hematoma with motor weakness after trigger point injection: A case report.
    Medicine, 2017, Volume: 96, Issue:39

    Topics: Aged; Biopsy, Fine-Needle; Buttocks; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; F

2017
Bleeding outcomes associated with coronary artery bypass graft surgery and recent clopidogrel exposure.
    The heart surgery forum, 2013, Volume: 16, Issue:2

    Topics: Causality; Clopidogrel; Comorbidity; Coronary Artery Bypass; Drug-Related Side Effects and Adverse R

2013
Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:1

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aspirin; Child; Child, Preschool;

2014
[Drug-drug interactions in nursing home patients].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2014, May-27, Volume: 134, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Clopidogrel; Databases, Factual; Dopa

2014
Exploring consumer opinions on the presentation of side-effects information in Australian Consumer Medicine Information leaflets.
    Health expectations : an international journal of public participation in health care and health policy, 2016, Volume: 19, Issue:3

    Topics: Aged; Antihypertensive Agents; Attitude; Clopidogrel; Cognition; Drug-Related Side Effects and Adver

2016
Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts.
    International journal of medical informatics, 2016, Volume: 86

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Clopidogrel; Cytochrome P-450 CYP2C19; Decision Supp

2016
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human

2016
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
    Journal of thrombosis and thrombolysis, 2009, Volume: 28, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru

2009
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:4

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A

2009
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh

2010
Lack of complications in skin surgery of patients receiving clopidogrel as compared with patients taking aspirin, warfarin, and controls.
    The American surgeon, 2010, Volume: 76, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Dermatologic Surgical Procedures;

2010
Low risk of intracranial and systemic hemorrhages in patients on dual antiplatelet treatment beyond 1 month following neuroendovascular angioplasty and/or stent placement.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2012, Volume: 22, Issue:1

    Topics: Angioplasty; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Combined Modality Therapy; Comorbidity;

2012
[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
    Klinicheskaia meditsina, 2010, Volume: 88, Issue:2

    Topics: Atorvastatin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A

2010
[Active pharmacosurveillance of patients affiliated to the Colombian general social security/health system].
    Revista de salud publica (Bogota, Colombia), 2010, Volume: 12, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Calcium Channel Blockers; Clopidogrel; Colombia; Diphosphon

2010
Drug interaction study between bupropion and ticlopidine in male CF-1 mice.
    Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:3

    Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Brain; Bupropion; Cytochrome P-450 CYP2B6;

2011
Clinical update on nursing home medicine: 2011.
    Journal of the American Medical Directors Association, 2011, Volume: 12, Issue:9

    Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delir

2011
Preemptive genotyping trialed to prevent adverse drug reactions.
    Nature medicine, 2011, Nov-07, Volume: 17, Issue:11

    Topics: Clinical Trials as Topic; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Genetic Test

2011
In vitro evaluation of the potential for drug-induced toxicity based on (35)S-labeled glutathione adduct formation and daily dose.
    Bioanalysis, 2012, Volume: 4, Issue:3

    Topics: Diclofenac; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Glutathio

2012
Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures.
    Pacing and clinical electrophysiology : PACE, 2012, Volume: 35, Issue:5

    Topics: Cardiac Resynchronization Therapy; Case-Control Studies; Clopidogrel; Comorbidity; Drug-Related Side

2012
Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation.
    Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:4

    Topics: Aged; Blood Vessel Prosthesis Implantation; Chemical and Drug Induced Liver Injury; Coronary Thrombo

2007
Admissions to a medical intensive care unit related to adverse drug reactions.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Sep-01, Volume: 64, Issue:17

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse

2007
STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.
    International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:2

    Topics: Abbreviations as Topic; Age Factors; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2008
STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.
    International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:2

    Topics: Abbreviations as Topic; Age Factors; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2008
STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.
    International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:2

    Topics: Abbreviations as Topic; Age Factors; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2008
STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.
    International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:2

    Topics: Abbreviations as Topic; Age Factors; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2008